Unrelated Double Umbilical Cord Blood Units Transplantation

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of unrelated double umbilical cord blood units Transplantation in patients with haematological malignancies using Antithymocyte Globulin Cyclophosphamide, busulfan as conditioning and cyclosporin, methylprednisolone as GVHD prophylaxis.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoblastic, Acute
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia, Myeloid, Chronic
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT01015742
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact	Ardeshir Ghavamzadeh, MD
Phone	84902635
Email	ghavamza@sina.tums.ac.ir
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	November 2009
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319587` - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Active, not recruiting	`NCT04090736` - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy	Phase 3
Completed	`NCT01617226` - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS	Phase 2
Terminated	`NCT00916045` - Pilot Study of Unrelated Cord Blood Transplantation	Phase 2
Terminated	`NCT00957580` - Trial of Pimasertib in Hematological Malignancies	Phase 2
Completed	`NCT00640796` - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors	Phase 1
Completed	`NCT00458250` - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H	Phase 1
Active, not recruiting	`NCT05424380` - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS	Phase 1
Completed	`NCT01690624` - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse	Phase 1
Recruiting	`NCT05471700` - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients	Phase 1/Phase 2
Not yet recruiting	`NCT05016063` - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia	Early Phase 1
Not yet recruiting	`NCT04450784` - ObServatory Children Acute RElated Therapy Leukemia
Recruiting	`NCT04265963` - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT04968860` - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting	`NCT03793517` - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT	Phase 2/Phase 3
Terminated	`NCT02841540` - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes	Phase 1
Recruiting	`NCT05453903` - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies	Phase 1
Completed	`NCT03720366` - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients	Phase 1
Withdrawn	`NCT04230564` - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated	`NCT03761069` - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias	Phase 1